查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1615419

基因组测试市场：按组件、技术、应用、分销管道、最终用途划分 - 2025-2030 年全球预测

Genome Testing Market by Component (Consumables, Equipment, Software & Services), Technology (Microarrays, Next-Generation Sequencing, Targeted Sequencing), Application, Distribution Channel, End-use - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 181 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2023年基因组检测市值为175.7亿美元，预计到2024年将达到197.6亿美元，复合年增长率为13.21%，预计到2030年将达到419亿美元。

基因组测试，包括基因型鉴定和定序，是现代医疗保健、研究和个人化医疗的宝贵工具。其范围包括检测疾病的遗传倾向、确定治疗策略和支持药物开发。基因组测试的需求在于能够根据个人的遗传倾向进行个人化治疗，实现早期疾病检测和预防性护理，并改善患者的治疗结果和成本效率。应用涵盖各个领域，从临床诊断和药物研究到农业和家谱研究。最终用户范围从医疗保健提供者和研究机构到寻求个人化健康见解的消费者。

主要市场统计
基准年[2023] 175.7亿美元
预测年份 [2024] 197.6亿美元
预测年份 [2030] 419亿美元
复合年增长率（%） 13.21%

由于技术进步、定序成本降低以及个人化医疗需求的增加，基因组测试市场正在迅速发展。关键的成长要素包括公众对遗传疾病的认识提高、政府支持措施以及精准医学应用的扩大。机会包括开发可携式基因组定序仪、将人工智慧和机器学习整合到基因组学中，以及扩大基因组学在医疗保健以外领域的使用，例如法医学和生物资讯学。为了抓住这些机会，公司应该专注于开发用户友好且负担得起的测试解决方案和强大的资料分析平台。

然而，这个市场面临着资料隐私问题、基因资料使用的道德问题以及跨地区缺乏标准化监管等限制。挑战包括由于隐私问题和遗传知识的潜在心理影响而阻碍消费者采用的障碍。成功减少这些障碍为创新创造了空间，特别是在加强资料保护措施和製定更清晰的法规结构。

为了实现持续成长，公司正在优先考虑 CRISPR 等基因组编辑技术的创新，探索与科技公司合作以推动数位健康解决方案，并揭示基因检测的好处并确保道德。基因组检测市场高度活跃，其特点是技术不断进步，并逐渐转向更全面、全面的健康解决方案。

市场动态：揭示快速发展的基因组测试市场的关键市场洞察

供需的动态交互作用正在改变基因组检测市场。透过了解这些不断变化的市场动态，公司可以准备好做出明智的投资决策、完善策略决策并抓住新的商机。全面了解这些趋势可以帮助企业降低政治、地理、技术、社会和经济领域的风险，同时也能帮助消费行为及其对製造业的影响。

  • 市场驱动因素
    • 全球遗传疾病和癌症盛行率不断上升
    • 越来越重视疾病的早期发现与预防
    • 个人化医疗意识不断增强
  • 市场限制因素
    • 与基因组设备相关的高成本
  • 市场机会
    • 基因序列测定和资料分析的技术进步
    • 增加政府措施和资金以促进研究活动
  • 市场挑战
    • 与解释遗传讯息相关的复杂性

波特五力：驾驭基因组测试市场的策略工具

波特的五力框架是了解市场竞争格局的重要工具。波特的五力框架为评估公司的竞争地位和探索策略机会提供了清晰的方法。该框架可帮助公司评估市场动态并确定新业务的盈利。这些见解使公司能够利用自己的优势，解决弱点并避免潜在的挑战，从而确保更强大的市场地位。

PESTLE分析：了解基因组检测市场的外部影响

外部宏观环境因素在塑造基因组检测市场的绩效动态方面发挥着至关重要的作用。对政治、经济、社会、技术、法律和环境因素的分析提供了应对这些影响所需的资讯。透过调查 PESTLE 因素，公司可以更了解潜在的风险和机会。这种分析可以帮助公司预测法规、消费者偏好和经济趋势的变化，并帮助他们做出积极主动的决策。

市场占有率分析 了解基因组检测市场的竞争状况

基因组测试市场的详细市场占有率分析可以对供应商绩效进行全面评估。公司可以透过比较收益、客户群和成长率等关键指标来揭示其竞争地位。该分析揭示了市场集中、分散和整合的趋势，为供应商提供了製定策略决策所需的洞察力，使他们能够在日益激烈的竞争中占有一席之地。

FPNV定位矩阵基因组测试市场供应商绩效评估

FPNV定位矩阵是评估基因组检测市场供应商的重要工具。此矩阵允许业务组织根据商务策略和产品满意度评估供应商，从而做出与其目标相符的明智决策。这四个象限使您能够清晰、准确地划分供应商，并确定最能满足您的策略目标的合作伙伴和解决方案。

策略分析和建议绘製基因组测试市场的成功之路

对于旨在加强其在全球市场的影响力的公司来说，基因组测试市场的策略分析至关重要。透过考虑关键资源、能力和绩效指标，公司可以识别成长机会并努力改进。这种方法使您能够克服竞争环境中的挑战，利用新的商机并取得长期成功。

本报告对市场进行了全面分析，涵盖关键重点领域：

1. 市场渗透率：详细检视当前市场环境、主要企业的广泛资料、评估其在市场中的影响力和整体影响力。

2. 市场开拓：辨识新兴市场的成长机会，评估现有领域的扩张潜力，并提供未来成长的策略蓝图。

3. 市场多元化：分析近期产品发布、开拓地区、关键产业进展、塑造市场的策略投资。

4. 竞争评估与情报：彻底分析竞争格局，检验市场占有率、业务策略、产品系列、认证、监理核准、专利趋势、主要企业的技术进步等。

5. 产品开发与创新：重点在于有望推动未来市场成长的最尖端科技、研发活动和产品创新。

我们也回答重要问题，帮助相关人员做出明智的决策：

1.目前的市场规模和未来的成长预测是多少？

2. 哪些产品、区隔市场和地区提供最佳投资机会？

3.塑造市场的主要技术趋势和监管影响是什么？

4.主要厂商的市场占有率和竞争地位如何？

5. 推动供应商市场进入和退出策略的收益来源和策略机会是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 全球遗传疾病和癌症的发生率正在增加
      • 疾病的早​​期发现和预防变得越来越重要
      • 个人化医疗意识不断增强
    • 抑制因素
      • 与基因组设备相关的高成本
    • 机会
      • 基因序列分析与资料分析的技术进步
      • 政府加大力度和资助以促进研究活动
    • 任务
      • 与解释遗传讯息相关的复杂性
  • 市场区隔分析
    • 组成部分：高通量定序设备的不断进步
    • 技术：准确、全面的基因组分析提高了次世代定序的普及度
    • 应用：增加对先进基因组测试的投资
    • 最终用途：先进基因组学在诊断实验室中对遗传疾病研究的重要性日益增加
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 经济
    • 社群
    • 技术的
    • 合法地
    • 环境

第六章 基因组测试市场：依组成部分

  • 消耗品
  • 装置
  • 软体和服务

第七章 基因组测试市场：依技术分类

  • 微阵列
  • 次世代定序
  • 标靶定序
  • 全基因组序列分析

第八章 基因组测试市场：依应用分类

  • 癌症
    • 脑肿瘤
    • 乳癌
    • 大肠直肠癌
    • 肺癌
    • 恶性黑色素瘤
    • 卵巢癌
    • 摄护腺癌
  • 非癌症
    • 心血管疾病
    • 神经系统疾病
    • 瘤

第九章 基因组测试市场：依分销管道划分

  • 离线
  • 在线的

第 10 章 基因组测试市场：依最终用途

  • 诊断实验室
  • 医院/诊所

第十一章 美洲基因组检测市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第十二章 亚太地区基因体检测市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十三章 欧洲、中东、非洲基因组检测市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第14章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
    • Corn Health 为 100,000 人基因组计划做准备
    • Illumina 推出先进的液态生物检体技术，可对固态肿瘤进行全面的基因组分析
    • 阿波罗在清奈开设基因组研究所，并计划在 2023 年再开设三所
  • 战略分析和建议

公司名单

  • 10x Genomics
  • 23andMe, Inc
  • Abbott Laboratories
  • Agilent Technologies, Inc.
  • BGI Group
  • Bio-Rad Laboratories, Inc.
  • Danaher Corporation
  • Eurofins Scientific SE
  • F. Hoffmann-La Roche, Ltd.
  • Freenome Holdings, Inc.
  • GeneDx, LLC
  • Genomic Testing Cooperative
  • Helix OpCo, LLC
  • Illumina, Inc.
  • Merck KGaA
  • New England Biolabs, Inc.
  • Novogene Co, Ltd.
  • Oxford Nanopore Technologies PLC
  • PerkinElmer Inc.
  • QIAGEN NV
  • Quest Diagnostics Incorporated
  • Takara Bio Inc
  • Thermo Fisher Scientific Inc.
  • Ultima Genomics, Inc.
  • VWR International, LLC
Product Code: MRR-647F3A880B41

The Genome Testing Market was valued at USD 17.57 billion in 2023, expected to reach USD 19.76 billion in 2024, and is projected to grow at a CAGR of 13.21%, to USD 41.90 billion by 2030.

Genome testing, encompassing both genotyping and sequencing, is an invaluable tool in modern healthcare, research, and personalized medicine. Its scope includes detecting genetic predispositions to diseases, guiding treatment decisions, and aiding in drug development. The necessity of genome testing is driven by its potential to personalize medical treatments based on an individual's genetic makeup, enabling early disease detection and preventative healthcare, which enhances patient outcomes and cost efficiency. Applications extend across various sectors, from clinical diagnostics and pharmaceutical research to agriculture and ancestry tracing. End users range from healthcare providers and research institutions to consumers seeking personalized health insights.

KEY MARKET STATISTICS
Base Year [2023] USD 17.57 billion
Estimated Year [2024] USD 19.76 billion
Forecast Year [2030] USD 41.90 billion
CAGR (%) 13.21%

The market for genome testing is rapidly evolving, spurred by technological advancements, decreasing costs of sequencing, and increasing demand for personalized medicine. Key growth influencers include increased public awareness of genetic diseases, supportive government initiatives, and expanding applications in precision medicine. Opportunities arise from the development of portable genome sequencers, integration of AI and machine learning in genomics, and expanding the use of genomics in non-healthcare fields such as forensic sciences and bioinformatics. To seize these opportunities, companies should focus on developing user-friendly, affordable testing solutions and robust data analytics platforms.

However, the market faces limitations such as data privacy concerns, ethical issues regarding genetic data usage, and a lack of standardized regulations across regions. Challenges include barriers to consumer adoption due to privacy worries and potential psychological impacts of genetic knowledge. Achievements in reducing these hurdles present room for innovation, particularly in enhancing data protection measures and in developing clearer regulatory frameworks.

For sustained growth, businesses should prioritize innovation in genome editing technologies like CRISPR, explore partnerships with technology firms to enhance digital health solutions, and invest in the educational outreach to demystify genetic testing benefits and address ethical concerns. The genome testing market is highly dynamic, marked by continuous advancements in technology and a gradual shift towards more comprehensive and integrated health solutions.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Genome Testing Market

The Genome Testing Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Increasing prevalence of genetic disorders and cancer across the globe
    • Growing emphasis on early disease detection & prevention
    • Increasing awareness of personalized medicine
  • Market Restraints
    • High cost associated with genomics equipment
  • Market Opportunities
    • Technological advancements in gene sequencing and data analysis
    • Rising government initiatives and fundings for boosting research activities
  • Market Challenges
    • Complexities associated with the interpreting genetic information

Porter's Five Forces: A Strategic Tool for Navigating the Genome Testing Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Genome Testing Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Genome Testing Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Genome Testing Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Genome Testing Market

A detailed market share analysis in the Genome Testing Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Genome Testing Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Genome Testing Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Genome Testing Market

A strategic analysis of the Genome Testing Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Genome Testing Market, highlighting leading vendors and their innovative profiles. These include 10x Genomics, 23andMe, Inc, Abbott Laboratories, Agilent Technologies, Inc., BGI Group, Bio-Rad Laboratories, Inc., Danaher Corporation, Eurofins Scientific SE, F. Hoffmann-La Roche, Ltd., Freenome Holdings, Inc., GeneDx, LLC, Genomic Testing Cooperative, Helix OpCo, LLC, Illumina, Inc., Merck KGaA, New England Biolabs, Inc., Novogene Co, Ltd., Oxford Nanopore Technologies PLC, PerkinElmer Inc., QIAGEN N.V., Quest Diagnostics Incorporated, Takara Bio Inc, Thermo Fisher Scientific Inc., Ultima Genomics, Inc., and VWR International, LLC.

Market Segmentation & Coverage

This research report categorizes the Genome Testing Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Component, market is studied across Consumables, Equipment, and Software & Services.
  • Based on Technology, market is studied across Microarrays, Next-Generation Sequencing, Targeted Sequencing, and Whole Genome Sequencing.
  • Based on Application, market is studied across Cancer and Non-cancer. The Cancer is further studied across Brain Cancer, Breast Cancer, Colorectal Cancer, Lung Cancer, Melanoma, Ovarian Cancer, and Prostate Cancer. The Non-cancer is further studied across Cardiovascular Diseases, Neurological Disorders, and Tumors.
  • Based on Distribution Channel, market is studied across Offline and Online.
  • Based on End-use, market is studied across Diagnostic Laboratories and Hospitals & Clinics.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increasing prevalence of genetic disorders and cancer across the globe
      • 5.1.1.2. Growing emphasis on early disease detection & prevention
      • 5.1.1.3. Increasing awareness of personalized medicine
    • 5.1.2. Restraints
      • 5.1.2.1. High cost associated with genomics equipment
    • 5.1.3. Opportunities
      • 5.1.3.1. Technological advancements in gene sequencing and data analysis
      • 5.1.3.2. Rising government initiatives and fundings for boosting research activities
    • 5.1.4. Challenges
      • 5.1.4.1. Complexities associated with the interpreting genetic information
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Component: Ongoing advancements in equipments for high-throughput sequencing
    • 5.2.2. Technology: Increasing preference of next-generation sequencing due to its precise and comprehensive genomic analysis
    • 5.2.3. Application: Increasing investment for advance genome testing across
    • 5.2.4. End-use: Rising significance of advanced genomic in diagnostic laboratories for research associated with genetic diseases
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Genome Testing Market, by Component

  • 6.1. Introduction
  • 6.2. Consumables
  • 6.3. Equipment
  • 6.4. Software & Services

7. Genome Testing Market, by Technology

  • 7.1. Introduction
  • 7.2. Microarrays
  • 7.3. Next-Generation Sequencing
  • 7.4. Targeted Sequencing
  • 7.5. Whole Genome Sequencing

8. Genome Testing Market, by Application

  • 8.1. Introduction
  • 8.2. Cancer
    • 8.2.1. Brain Cancer
    • 8.2.2. Breast Cancer
    • 8.2.3. Colorectal Cancer
    • 8.2.4. Lung Cancer
    • 8.2.5. Melanoma
    • 8.2.6. Ovarian Cancer
    • 8.2.7. Prostate Cancer
  • 8.3. Non-cancer
    • 8.3.1. Cardiovascular Diseases
    • 8.3.2. Neurological Disorders
    • 8.3.3. Tumors

9. Genome Testing Market, by Distribution Channel

  • 9.1. Introduction
  • 9.2. Offline
  • 9.3. Online

10. Genome Testing Market, by End-use

  • 10.1. Introduction
  • 10.2. Diagnostic Laboratories
  • 10.3. Hospitals & Clinics

11. Americas Genome Testing Market

  • 11.1. Introduction
  • 11.2. Argentina
  • 11.3. Brazil
  • 11.4. Canada
  • 11.5. Mexico
  • 11.6. United States

12. Asia-Pacific Genome Testing Market

  • 12.1. Introduction
  • 12.2. Australia
  • 12.3. China
  • 12.4. India
  • 12.5. Indonesia
  • 12.6. Japan
  • 12.7. Malaysia
  • 12.8. Philippines
  • 12.9. Singapore
  • 12.10. South Korea
  • 12.11. Taiwan
  • 12.12. Thailand
  • 12.13. Vietnam

13. Europe, Middle East & Africa Genome Testing Market

  • 13.1. Introduction
  • 13.2. Denmark
  • 13.3. Egypt
  • 13.4. Finland
  • 13.5. France
  • 13.6. Germany
  • 13.7. Israel
  • 13.8. Italy
  • 13.9. Netherlands
  • 13.10. Nigeria
  • 13.11. Norway
  • 13.12. Poland
  • 13.13. Qatar
  • 13.14. Russia
  • 13.15. Saudi Arabia
  • 13.16. South Africa
  • 13.17. Spain
  • 13.18. Sweden
  • 13.19. Switzerland
  • 13.20. Turkey
  • 13.21. United Arab Emirates
  • 13.22. United Kingdom

14. Competitive Landscape

  • 14.1. Market Share Analysis, 2023
  • 14.2. FPNV Positioning Matrix, 2023
  • 14.3. Competitive Scenario Analysis
    • 14.3.1. Cone Health Readies for 100,000 Person Genomics Project
    • 14.3.2. Illumina Launches Advanced Liquid Biopsy Assay to Enable Comprehensive Genomic Profiling of Solid Tumors
    • 14.3.3. Apollo Opens Genomic Institute In Chennai, to Open Three More in 2023
  • 14.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. 10x Genomics
  • 2. 23andMe, Inc
  • 3. Abbott Laboratories
  • 4. Agilent Technologies, Inc.
  • 5. BGI Group
  • 6. Bio-Rad Laboratories, Inc.
  • 7. Danaher Corporation
  • 8. Eurofins Scientific SE
  • 9. F. Hoffmann-La Roche, Ltd.
  • 10. Freenome Holdings, Inc.
  • 11. GeneDx, LLC
  • 12. Genomic Testing Cooperative
  • 13. Helix OpCo, LLC
  • 14. Illumina, Inc.
  • 15. Merck KGaA
  • 16. New England Biolabs, Inc.
  • 17. Novogene Co, Ltd.
  • 18. Oxford Nanopore Technologies PLC
  • 19. PerkinElmer Inc.
  • 20. QIAGEN N.V.
  • 21. Quest Diagnostics Incorporated
  • 22. Takara Bio Inc
  • 23. Thermo Fisher Scientific Inc.
  • 24. Ultima Genomics, Inc.
  • 25. VWR International, LLC

LIST OF FIGURES

  • FIGURE 1. GENOME TESTING MARKET RESEARCH PROCESS
  • FIGURE 2. GENOME TESTING MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL GENOME TESTING MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL GENOME TESTING MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL GENOME TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL GENOME TESTING MARKET SIZE, BY COMPONENT, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL GENOME TESTING MARKET SIZE, BY COMPONENT, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL GENOME TESTING MARKET SIZE, BY TECHNOLOGY, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL GENOME TESTING MARKET SIZE, BY TECHNOLOGY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL GENOME TESTING MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL GENOME TESTING MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL GENOME TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL GENOME TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. GLOBAL GENOME TESTING MARKET SIZE, BY END-USE, 2023 VS 2030 (%)
  • FIGURE 15. GLOBAL GENOME TESTING MARKET SIZE, BY END-USE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. AMERICAS GENOME TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. AMERICAS GENOME TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. UNITED STATES GENOME TESTING MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 19. UNITED STATES GENOME TESTING MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. ASIA-PACIFIC GENOME TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 21. ASIA-PACIFIC GENOME TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. EUROPE, MIDDLE EAST & AFRICA GENOME TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 23. EUROPE, MIDDLE EAST & AFRICA GENOME TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 24. GENOME TESTING MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 25. GENOME TESTING MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. GENOME TESTING MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL GENOME TESTING MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL GENOME TESTING MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL GENOME TESTING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. GENOME TESTING MARKET DYNAMICS
  • TABLE 7. GLOBAL GENOME TESTING MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL GENOME TESTING MARKET SIZE, BY CONSUMABLES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL GENOME TESTING MARKET SIZE, BY EQUIPMENT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL GENOME TESTING MARKET SIZE, BY SOFTWARE & SERVICES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL GENOME TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL GENOME TESTING MARKET SIZE, BY MICROARRAYS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL GENOME TESTING MARKET SIZE, BY NEXT-GENERATION SEQUENCING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL GENOME TESTING MARKET SIZE, BY TARGETED SEQUENCING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL GENOME TESTING MARKET SIZE, BY WHOLE GENOME SEQUENCING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL GENOME TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL GENOME TESTING MARKET SIZE, BY CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL GENOME TESTING MARKET SIZE, BY BRAIN CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL GENOME TESTING MARKET SIZE, BY BREAST CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL GENOME TESTING MARKET SIZE, BY COLORECTAL CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL GENOME TESTING MARKET SIZE, BY LUNG CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL GENOME TESTING MARKET SIZE, BY MELANOMA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL GENOME TESTING MARKET SIZE, BY OVARIAN CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL GENOME TESTING MARKET SIZE, BY PROSTATE CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL GENOME TESTING MARKET SIZE, BY CANCER, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL GENOME TESTING MARKET SIZE, BY NON-CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 27. GLOBAL GENOME TESTING MARKET SIZE, BY CARDIOVASCULAR DISEASES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 28. GLOBAL GENOME TESTING MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 29. GLOBAL GENOME TESTING MARKET SIZE, BY TUMORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 30. GLOBAL GENOME TESTING MARKET SIZE, BY NON-CANCER, 2018-2030 (USD MILLION)
  • TABLE 31. GLOBAL GENOME TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 32. GLOBAL GENOME TESTING MARKET SIZE, BY OFFLINE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 33. GLOBAL GENOME TESTING MARKET SIZE, BY ONLINE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 34. GLOBAL GENOME TESTING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 35. GLOBAL GENOME TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 36. GLOBAL GENOME TESTING MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 37. AMERICAS GENOME TESTING MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 38. AMERICAS GENOME TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 39. AMERICAS GENOME TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 40. AMERICAS GENOME TESTING MARKET SIZE, BY CANCER, 2018-2030 (USD MILLION)
  • TABLE 41. AMERICAS GENOME TESTING MARKET SIZE, BY NON-CANCER, 2018-2030 (USD MILLION)
  • TABLE 42. AMERICAS GENOME TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 43. AMERICAS GENOME TESTING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 44. AMERICAS GENOME TESTING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 45. ARGENTINA GENOME TESTING MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 46. ARGENTINA GENOME TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 47. ARGENTINA GENOME TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 48. ARGENTINA GENOME TESTING MARKET SIZE, BY CANCER, 2018-2030 (USD MILLION)
  • TABLE 49. ARGENTINA GENOME TESTING MARKET SIZE, BY NON-CANCER, 2018-2030 (USD MILLION)
  • TABLE 50. ARGENTINA GENOME TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 51. ARGENTINA GENOME TESTING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 52. BRAZIL GENOME TESTING MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 53. BRAZIL GENOME TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 54. BRAZIL GENOME TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 55. BRAZIL GENOME TESTING MARKET SIZE, BY CANCER, 2018-2030 (USD MILLION)
  • TABLE 56. BRAZIL GENOME TESTING MARKET SIZE, BY NON-CANCER, 2018-2030 (USD MILLION)
  • TABLE 57. BRAZIL GENOME TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 58. BRAZIL GENOME TESTING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 59. CANADA GENOME TESTING MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 60. CANADA GENOME TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 61. CANADA GENOME TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 62. CANADA GENOME TESTING MARKET SIZE, BY CANCER, 2018-2030 (USD MILLION)
  • TABLE 63. CANADA GENOME TESTING MARKET SIZE, BY NON-CANCER, 2018-2030 (USD MILLION)
  • TABLE 64. CANADA GENOME TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 65. CANADA GENOME TESTING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 66. MEXICO GENOME TESTING MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 67. MEXICO GENOME TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 68. MEXICO GENOME TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 69. MEXICO GENOME TESTING MARKET SIZE, BY CANCER, 2018-2030 (USD MILLION)
  • TABLE 70. MEXICO GENOME TESTING MARKET SIZE, BY NON-CANCER, 2018-2030 (USD MILLION)
  • TABLE 71. MEXICO GENOME TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 72. MEXICO GENOME TESTING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 73. UNITED STATES GENOME TESTING MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 74. UNITED STATES GENOME TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 75. UNITED STATES GENOME TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 76. UNITED STATES GENOME TESTING MARKET SIZE, BY CANCER, 2018-2030 (USD MILLION)
  • TABLE 77. UNITED STATES GENOME TESTING MARKET SIZE, BY NON-CANCER, 2018-2030 (USD MILLION)
  • TABLE 78. UNITED STATES GENOME TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 79. UNITED STATES GENOME TESTING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 80. UNITED STATES GENOME TESTING MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 81. ASIA-PACIFIC GENOME TESTING MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 82. ASIA-PACIFIC GENOME TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 83. ASIA-PACIFIC GENOME TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 84. ASIA-PACIFIC GENOME TESTING MARKET SIZE, BY CANCER, 2018-2030 (USD MILLION)
  • TABLE 85. ASIA-PACIFIC GENOME TESTING MARKET SIZE, BY NON-CANCER, 2018-2030 (USD MILLION)
  • TABLE 86. ASIA-PACIFIC GENOME TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 87. ASIA-PACIFIC GENOME TESTING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 88. ASIA-PACIFIC GENOME TESTING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 89. AUSTRALIA GENOME TESTING MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 90. AUSTRALIA GENOME TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 91. AUSTRALIA GENOME TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 92. AUSTRALIA GENOME TESTING MARKET SIZE, BY CANCER, 2018-2030 (USD MILLION)
  • TABLE 93. AUSTRALIA GENOME TESTING MARKET SIZE, BY NON-CANCER, 2018-2030 (USD MILLION)
  • TABLE 94. AUSTRALIA GENOME TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 95. AUSTRALIA GENOME TESTING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 96. CHINA GENOME TESTING MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 97. CHINA GENOME TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 98. CHINA GENOME TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 99. CHINA GENOME TESTING MARKET SIZE, BY CANCER, 2018-2030 (USD MILLION)
  • TABLE 100. CHINA GENOME TESTING MARKET SIZE, BY NON-CANCER, 2018-2030 (USD MILLION)
  • TABLE 101. CHINA GENOME TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 102. CHINA GENOME TESTING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 103. INDIA GENOME TESTING MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 104. INDIA GENOME TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 105. INDIA GENOME TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 106. INDIA GENOME TESTING MARKET SIZE, BY CANCER, 2018-2030 (USD MILLION)
  • TABLE 107. INDIA GENOME TESTING MARKET SIZE, BY NON-CANCER, 2018-2030 (USD MILLION)
  • TABLE 108. INDIA GENOME TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 109. INDIA GENOME TESTING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 110. INDONESIA GENOME TESTING MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 111. INDONESIA GENOME TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 112. INDONESIA GENOME TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 113. INDONESIA GENOME TESTING MARKET SIZE, BY CANCER, 2018-2030 (USD MILLION)
  • TABLE 114. INDONESIA GENOME TESTING MARKET SIZE, BY NON-CANCER, 2018-2030 (USD MILLION)
  • TABLE 115. INDONESIA GENOME TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 116. INDONESIA GENOME TESTING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 117. JAPAN GENOME TESTING MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 118. JAPAN GENOME TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 119. JAPAN GENOME TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 120. JAPAN GENOME TESTING MARKET SIZE, BY CANCER, 2018-2030 (USD MILLION)
  • TABLE 121. JAPAN GENOME TESTING MARKET SIZE, BY NON-CANCER, 2018-2030 (USD MILLION)
  • TABLE 122. JAPAN GENOME TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 123. JAPAN GENOME TESTING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 124. MALAYSIA GENOME TESTING MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 125. MALAYSIA GENOME TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 126. MALAYSIA GENOME TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 127. MALAYSIA GENOME TESTING MARKET SIZE, BY CANCER, 2018-2030 (USD MILLION)
  • TABLE 128. MALAYSIA GENOME TESTING MARKET SIZE, BY NON-CANCER, 2018-2030 (USD MILLION)
  • TABLE 129. MALAYSIA GENOME TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 130. MALAYSIA GENOME TESTING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 131. PHILIPPINES GENOME TESTING MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 132. PHILIPPINES GENOME TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 133. PHILIPPINES GENOME TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 134. PHILIPPINES GENOME TESTING MARKET SIZE, BY CANCER, 2018-2030 (USD MILLION)
  • TABLE 135. PHILIPPINES GENOME TESTING MARKET SIZE, BY NON-CANCER, 2018-2030 (USD MILLION)
  • TABLE 136. PHILIPPINES GENOME TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 137. PHILIPPINES GENOME TESTING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 138. SINGAPORE GENOME TESTING MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 139. SINGAPORE GENOME TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 140. SINGAPORE GENOME TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 141. SINGAPORE GENOME TESTING MARKET SIZE, BY CANCER, 2018-2030 (USD MILLION)
  • TABLE 142. SINGAPORE GENOME TESTING MARKET SIZE, BY NON-CANCER, 2018-2030 (USD MILLION)
  • TABLE 143. SINGAPORE GENOME TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 144. SINGAPORE GENOME TESTING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 145. SOUTH KOREA GENOME TESTING MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 146. SOUTH KOREA GENOME TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 147. SOUTH KOREA GENOME TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 148. SOUTH KOREA GENOME TESTING MARKET SIZE, BY CANCER, 2018-2030 (USD MILLION)
  • TABLE 149. SOUTH KOREA GENOME TESTING MARKET SIZE, BY NON-CANCER, 2018-2030 (USD MILLION)
  • TABLE 150. SOUTH KOREA GENOME TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 151. SOUTH KOREA GENOME TESTING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 152. TAIWAN GENOME TESTING MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 153. TAIWAN GENOME TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 154. TAIWAN GENOME TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 155. TAIWAN GENOME TESTING MARKET SIZE, BY CANCER, 2018-2030 (USD MILLION)
  • TABLE 156. TAIWAN GENOME TESTING MARKET SIZE, BY NON-CANCER, 2018-2030 (USD MILLION)
  • TABLE 157. TAIWAN GENOME TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 158. TAIWAN GENOME TESTING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 159. THAILAND GENOME TESTING MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 160. THAILAND GENOME TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 161. THAILAND GENOME TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 162. THAILAND GENOME TESTING MARKET SIZE, BY CANCER, 2018-2030 (USD MILLION)
  • TABLE 163. THAILAND GENOME TESTING MARKET SIZE, BY NON-CANCER, 2018-2030 (USD MILLION)
  • TABLE 164. THAILAND GENOME TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 165. THAILAND GENOME TESTING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 166. VIETNAM GENOME TESTING MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 167. VIETNAM GENOME TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 168. VIETNAM GENOME TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 169. VIETNAM GENOME TESTING MARKET SIZE, BY CANCER, 2018-2030 (USD MILLION)
  • TABLE 170. VIETNAM GENOME TESTING MARKET SIZE, BY NON-CANCER, 2018-2030 (USD MILLION)
  • TABLE 171. VIETNAM GENOME TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 172. VIETNAM GENOME TESTING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 173. EUROPE, MIDDLE EAST & AFRICA GENOME TESTING MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 174. EUROPE, MIDDLE EAST & AFRICA GENOME TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 175. EUROPE, MIDDLE EAST & AFRICA GENOME TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 176. EUROPE, MIDDLE EAST & AFRICA GENOME TESTING MARKET SIZE, BY CANCER, 2018-2030 (USD MILLION)
  • TABLE 177. EUROPE, MIDDLE EAST & AFRICA GENOME TESTING MARKET SIZE, BY NON-CANCER, 2018-2030 (USD MILLION)
  • TABLE 178. EUROPE, MIDDLE EAST & AFRICA GENOME TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 179. EUROPE, MIDDLE EAST & AFRICA GENOME TESTING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 180. EUROPE, MIDDLE EAST & AFRICA GENOME TESTING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 181. DENMARK GENOME TESTING MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 182. DENMARK GENOME TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 183. DENMARK GENOME TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 184. DENMARK GENOME TESTING MARKET SIZE, BY CANCER, 2018-2030 (USD MILLION)
  • TABLE 185. DENMARK GENOME TESTING MARKET SIZE, BY NON-CANCER, 2018-2030 (USD MILLION)
  • TABLE 186. DENMARK GENOME TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 187. DENMARK GENOME TESTING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 188. EGYPT GENOME TESTING MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 189. EGYPT GENOME TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 190. EGYPT GENOME TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 191. EGYPT GENOME TESTING MARKET SIZE, BY CANCER, 2018-2030 (USD MILLION)
  • TABLE 192. EGYPT GENOME TESTING MARKET SIZE, BY NON-CANCER, 2018-2030 (USD MILLION)
  • TABLE 193. EGYPT GENOME TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 194. EGYPT GENOME TESTING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 195. FINLAND GENOME TESTING MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 196. FINLAND GENOME TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 197. FINLAND GENOME TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 198. FINLAND GENOME TESTING MARKET SIZE, BY CANCER, 2018-2030 (USD MILLION)
  • TABLE 199. FINLAND GENOME TESTING MARKET SIZE, BY NON-CANCER, 2018-2030 (USD MILLION)
  • TABLE 200. FINLAND GENOME TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 201. FINLAND GENOME TESTING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 202. FRANCE GENOME TESTING MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 203. FRANCE GENOME TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 204. FRANCE GENOME TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 205. FRANCE GENOME TESTING MARKET SIZE, BY CANCER, 2018-2030 (USD MILLION)
  • TABLE 206. FRANCE GENOME TESTING MARKET SIZE, BY NON-CANCER, 2018-2030 (USD MILLION)
  • TABLE 207. FRANCE GENOME TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 208. FRANCE GENOME TESTING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 209. GERMANY GENOME TESTING MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 210. GERMANY GENOME TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 211. GERMANY GENOME TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 212. GERMANY GENOME TESTING MARKET SIZE, BY CANCER, 2018-2030 (USD MILLION)
  • TABLE 213. GERMANY GENOME TESTING MARKET SIZE, BY NON-CANCER, 2018-2030 (USD MILLION)
  • TABLE 214. GERMANY GENOME TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 215. GERMANY GENOME TESTING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 216. ISRAEL GENOME TESTING MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 217. ISRAEL GENOME TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 218. ISRAEL GENOME TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 219. ISRAEL GENOME TESTING MARKET SIZE, BY CANCER, 2018-2030 (USD MILLION)
  • TABLE 220. ISRAEL GENOME TESTING MARKET SIZE, BY NON-CANCER, 2018-2030 (USD MILLION)
  • TABLE 221. ISRAEL GENOME TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 222. ISRAEL GENOME TESTING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 223. ITALY GENOME TESTING MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 224. ITALY GENOME TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 225. ITALY GENOME TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 226. ITALY GENOME TESTING MARKET SIZE, BY CANCER, 2018-2030 (USD MILLION)
  • TABLE 227. ITALY GENOME TESTING MARKET SIZE, BY NON-CANCER, 2018-2030 (USD MILLION)
  • TABLE 228. ITALY GENOME TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 229. ITALY GENOME TESTING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 230. NETHERLANDS GENOME TESTING MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 231. NETHERLANDS GENOME TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 232. NETHERLANDS GENOME TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 233. NETHERLANDS GENOME TESTING MARKET SIZE, BY CANCER, 2018-2030 (USD MILLION)
  • TABLE 234. NETHERLANDS GENOME TESTING MARKET SIZE, BY NON-CANCER, 2018-2030 (USD MILLION)
  • TABLE 235. NETHERLANDS GENOME TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 236. NETHERLANDS GENOME TESTING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 237. NIGERIA GENOME TESTING MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 238. NIGERIA GENOME TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 239. NIGERIA GENOME TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 240. NIGERIA GENOME TESTING MARKET SIZE, BY CANCER, 2018-2030 (USD MILLION)
  • TABLE 241. NIGERIA GENOME TESTING MARKET SIZE, BY NON-CANCER, 2018-2030 (USD MILLION)
  • TABLE 242. NIGERIA GENOME TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 243. NIGERIA GENOME TESTING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 244. NORWAY GENOME TESTING MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 245. NORWAY GENOME TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 246. NORWAY GENOME TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 247. NORWAY GENOME TESTING MARKET SIZE, BY CANCER, 2018-2030 (USD MILLION)
  • TABLE 248. NORWAY GENOME TESTING MARKET SIZE, BY NON-CANCER, 2018-2030 (USD MILLION)
  • TABLE 249. NORWAY GENOME TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 250. NORWAY GENOME TESTING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 251. POLAND GENOME TESTING MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 252. POLAND GENOME TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 253. POLAND GENOME TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 254. POLAND GENOME TESTING MARKET SIZE, BY CANCER, 2018-2030 (USD MILLION)
  • TABLE 255. POLAND GENOME TESTING MARKET SIZE, BY NON-CANCER, 2018-2030 (USD MILLION)
  • TABLE 256. POLAND GENOME TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 257. POLAND GENOME TESTING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 258. QATAR GENOME TESTING MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 259. QATAR GENOME TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 260. QATAR GENOME TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 261. QATAR GENOME TESTING MARKET SIZE, BY CANCER, 2018-2030 (USD MILLION)
  • TABLE 262. QATAR GENOME TESTING MARKET SIZE, BY NON-CANCER, 2018-2030 (USD MILLION)
  • TABLE 263. QATAR GENOME TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 264. QATAR GENOME TESTING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 265. RUSSIA GENOME TESTING MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 266. RUSSIA GENOME TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 267. RUSSIA GENOME TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 268. RUSSIA GENOME TESTING MARKET SIZE, BY CANCER, 2018-2030 (USD MILLION)
  • TABLE 269. RUSSIA GENOME TESTING MARKET SIZE, BY NON-CANCER, 2018-2030 (USD MILLION)
  • TABLE 270. RUSSIA GENOME TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 271. RUSSIA GENOME TESTING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 272. SAUDI ARABIA GENOME TESTING MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 273. SAUDI ARABIA GENOME TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 274. SAUDI ARABIA GENOME TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 275. SAUDI ARABIA GENOME TESTING MARKET SIZE, BY CANCER, 2018-2030 (USD MILLION)
  • TABLE 276. SAUDI ARABIA GENOME TESTING MARKET SIZE, BY NON-CANCER, 2018-2030 (USD MILLION)
  • TABLE 277. SAUDI ARABIA GENOME TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 278. SAUDI ARABIA GENOME TESTING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 279. SOUTH AFRICA GENOME TESTING MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 280. SOUTH AFRICA GENOME TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 281. SOUTH AFRICA GENOME TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 282. SOUTH AFRICA GENOME TESTING MARKET SIZE, BY CANCER, 2018-2030 (USD MILLION)
  • TABLE 283. SOUTH AFRICA GENOME TESTING MARKET SIZE, BY NON-CANCER, 2018-2030 (USD MILLION)
  • TABLE 284. SOUTH AFRICA GENOME TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 285. SOUTH AFRICA GENOME TESTING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 286. SPAIN GENOME TESTING MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 287. SPAIN GENOME TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 288. SPAIN GENOME TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 289. SPAIN GENOME TESTING MARKET SIZE, BY CANCER, 2018-2030 (USD MILLION)
  • TABLE 290. SPAIN GENOME TESTING MARKET SIZE, BY NON-CANCER, 2018-2030 (USD MILLION)
  • TABLE 291. SPAIN GENOME TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 292. SPAIN GENOME TESTING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 293. SWEDEN GENOME TESTING MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 294. SWEDEN GENOME TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 295. SWEDEN GENOME TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 296. SWEDEN GENOME TESTING MARKET SIZE, BY CANCER, 2018-2030 (USD MILLION)
  • TABLE 297. SWEDEN GENOME TESTING MARKET SIZE, BY NON-CANCER, 2018-2030 (USD MILLION)
  • TABLE 298. SWEDEN GENOME TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 299. SWEDEN GENOME TESTING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 300. SWITZERLAND GENOME TESTING MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 301. SWITZERLAND GENOME TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 302. SWITZERLAND GENOME TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 303. SWITZERLAND GENOME TESTING MARKET SIZE, BY CANCER, 2018-2030 (USD MILLION)
  • TABLE 304. SWITZERLAND GENOME TESTING MARKET SIZE, BY NON-CANCER, 2018-2030 (USD MILLION)
  • TABLE 305. SWITZERLAND GENOME TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 306. SWITZERLAND GENOME TESTING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 307. TURKEY GENOME TESTING MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 308. TURKEY GENOME TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 309. TURKEY GENOME TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 310. TURKEY GENOME TESTING MARKET SIZE, BY CANCER, 2018-2030 (USD MILLION)
  • TABLE 311. TURKEY GENOME TESTING MARKET SIZE, BY NON-CANCER, 2018-2030 (USD MILLION)
  • TABLE 312. TURKEY GENOME TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 313. TURKEY GENOME TESTING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 314. UNITED ARAB EMIRATES GENOME TESTING MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 315. UNITED ARAB EMIRATES GENOME TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 316. UNITED ARAB EMIRATES GENOME TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 317. UNITED ARAB EMIRATES GENOME TESTING MARKET SIZE, BY CANCER, 2018-2030 (USD MILLION)
  • TABLE 318. UNITED ARAB EMIRATES GENOME TESTING MARKET SIZE, BY NON-CANCER, 2018-2030 (USD MILLION)
  • TABLE 319. UNITED ARAB EMIRATES GENOME TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 320. UNITED ARAB EMIRATES GENOME TESTING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 321. UNITED KINGDOM GENOME TESTING MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 322. UNITED KINGDOM GENOME TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 323. UNITED KINGDOM GENOME TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 324. UNITED KINGDOM GENOME TESTING MARKET SIZE, BY CANCER, 2018-2030 (USD MILLION)
  • TABLE 325. UNITED KINGDOM GENOME TESTING MARKET SIZE, BY NON-CANCER, 2018-2030 (USD MILLION)
  • TABLE 326. UNITED KINGDOM GENOME TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 327. UNITED KINGDOM GENOME TESTING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 328. GENOME TESTING MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 329. GENOME TESTING MARKET, FPNV POSITIONING MATRIX, 2023